The discovery of GlyMCA has overcome the issue of easy metabolism by bacterial bile salt hydrolase, which affects endogenous intestinal FXR antagonists, and has shown great potency in improving obesity and insulin resistance caused by lipid accumulation [5]. This evidence concerns the gene NR1H4 and obesity due to melanocortin 4 receptor deficiency.